Absolute read: PFS 6.7 vs 6.0 mo (+0.7 mo, HR 0.74). OS 21.0 vs 22.2 (HR 1.04) — no survival benefit. Statistical PFS ≠ clinical practice change in PD-L1 CPS≥1 HR+/HER2− mBC post-ET. #ESMO26
62 浏览 · 1 赞 · 1 转发 · 0 回复
Early clinical antitumor activity of VRN101099 across diverse HER2-mutants in solid tumors
https://esmocongress.esmo.orgHealth-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgA global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide
https://esmocongress.esmo.orgEfficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgGene-expression profiling of HR+/HER2- breast cancers arising in germline BRCA1/2 mutation carriers
https://esmocongress.esmo.org#ESMO26: Pembrolizumab plus chemotherapy reduced the risk of PFS by 26% in PD-L1-positive, HR-positive #AdvancedBreastCancer after failure on endocrine therapy in the phase III KEYNOTE-B49 🔗 https://ow.ly/5NoZ50ZZjCH #ClinicalTrial #BreastCancer #InsightsbyESMO @PTarantinoMD在 X 查看被引用的帖子
来源：Mustafa Özdoğan, MD · x.com